Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Hey! Dildos Sale in our Dildos Store!
Popular Articles

About 75% Of People In Rwanda Who Have Experienced Discrimination Are HIV-Positive, Survey Finds
A recently released survey on stigma in Rwanda indicates that at least 74% of people in various segments of society who have experienced discrimination are HIV-positive, the New Times/AllAfrica.com reports. The discrimination often is in the form of isolation from family and physical harassment, according to the survey. The study was conducted by the Association of Vulnerable Widows Infected and Affected by HIV and AIDS in conjunction with the Network of People Living with HIV and UNAIDS Rwanda. It found that although 87% of respondents reported never having been denied health services, 88% reported being denied other social services, such as family planning, because of their HIV status. An estimated one-third of respondents reported that their rights had been abused because of their HIV-positive status. Chantal Nyiramanyana, AVVAIS president, said, "We conducted this survey as a way of providing basis for advocacy, policy change, and programmatic interventions by the government and other interested bodies to address stigma and discrimination related to HIV." The survey found that other groups experiencing stigma in the country include commercial sex workers and asylum seekers (Kwizera, New Times/AllAfrica.com, 5/27).
drugs without prescription
Oral Health Center Has Focus On Disease As A Whole
Australia"s premier research centre for all aspects of oral health will be established at the University of Adelaide thanks to a $2.4 million Federal Government grant.
News of the day
MIT Study Sheds Light On The Brain's Ability To Change In Response To Learning
If you"ve ever felt doomed to repeat your mistakes, researchers at MIT"s Picower Institute for Learning and Memory may have explained why: Brain cells may only learn from experience when we do something right and not when we fail.
Diagnostics

Provectus Pharmaceuticals Initiates New PH-10 Clinical Study For Psoriasis

Provectus Pharmaceuticals, Inc. (OTC BB: PVCT ), a development-stage oncology and dermatology biopharmaceutical company, has initiated a new Phase 2 clinical trial of PH-10 for psoriasis involving daily dosing of patients for 28 days. After reviewing safety and efficacy data from its PH-10 trial for atopic dermatitis, Provectus determined that daily dosing of patients with psoriasis trial would be an appropriate and attractive regimen. The new study supplants an earlier Phase 2 study, using twice weekly dosing for 12 weeks, which was terminated earlier in June. Preliminary analysis of the data from the first six psoriasis patients to complete the earlier Phase 2 study showed that repeat treatment with PH-10 was safe, with evidence of efficacy noted in some subjects. This analysis, combined with the data obtained from the on-going atopic dermatitis study, indicated that increased dosing frequency was appropriate for psoriasis. The new protocol replaces twice weekly application of PH-10 with daily application. Enrollment in the new trial has commenced and the first patients have begun active participation at the first clinical site in Miami, FL. Patients interested in participating in the trial may find further information at the NIH clinical trials registry, www.clinicaltrials.gov or at http://www.pvct.com. Craig Dees, Ph.D., CEO of Provectus said, "PH-10 differs from most other advanced therapies for chronic skin conditions, like atopic dermatitis and psoriasis, because it"s topically applied, confining effects to diseased skin. This approach can improve efficacy and largely eliminates any potential for systemic side effects that have accompanied many recent systemic therapies." Dees concluded, "With this improved protocol that we believe will support robust data in a second dermatology indication, we have reached the point in the development of PH-10 where we are ready for either a licensing or co-development partnership. Therefore, part of our efforts in the months ahead will involve exploring these possibilities with major parties in the dermatology sector, while simultaneously continuing our clinical trials." According to the National Institutes of Health, as many as 7.5 million Americans, approximately 2.2 percent of the population, have psoriasis. The National Psoriasis Foundation reports that approximately 125 million people worldwide, 2 to 3 percent of the total population have psoriasis. It also reports that total direct and indirect health care costs of psoriasis for patients are approximately $11.25 billion annually. Provectus Pharmaceuticals, Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009